Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yuan-Hung Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Thymus Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Health Research Institutes, Taipei Medical University.
Abstract (Originalsprache)
Background
Systemic therapy is the primary treatment for advanced thymic malignancies. However, there is an urgent need to improve clinical outcome. Personalized treatment based on predictive biomarkers is a potential approach to address this requirement. In this study, we aimed to show the correlation between drug sensitivity tests on CTCs‐derived organoids and clinical response in patients with thymic malignancies. This approach carries the potential to create personalized cancer avatars and improve treatment outcome for patients.
Methods
We previously reported potential treatment outcome prediction with patient‐derived organoids (cancer avatars) in patients with pancreatic ductal adenocarcinoma. To further investigate the feasibility of this approach in advanced thymic malignancies, we conducted a study in which 12 patients were enrolled and 21 liquid biopsies were performed.
Results
Cancer avatars were successfully derived in 16 out of 21 samples (success rate 76.2%). We found a sensitivity of 1.0 and specificity of 0.6 for drug sensitivity tests on the cancer avatars, and a two‐tailed Fisher's exact test revealed a significant correlation between drug sensitivity tests and clinical responses ( p = 0.0275).
Conclusion
This study supports the potential of circulating tumor cell‐derived organoids to inform personalized treatment for advanced thymic malignancies. Further validation of this proof of concept finding is ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
- School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
- Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
- Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Taipei Cancer Center and Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
- Department of Radiation Oncology, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan.
ORCID-Profile: Yuan-Hung Wu, Chi-Lu Chiang, Peng-Yuan Wang
Förderung
- Ministry of Science and Technology, Taiwan
- National Health Research Institutes
- Taipei Medical University
Zitieren
APA
Wu, Y. H., Chao, H. S., Chiang, C. L., Luo, Y. H., Chiu, C. H., Yen, S. H., Liu, C. Y., Chiou, J. F., Burnouf, T., Chen, Y. J., Wang, P. Y., Chao, T. Y., Hsu, S. M., & Lu, L. S. (2023). Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15039
Vancouver
Wu YH, Chao HS, Chiang CL, Luo YH, Chiu CH, Yen SH, et al. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15039
BibTeX
@article{Wu2023,
author = {Wu, Yuan-Hung and Chao, Heng-Sheng and Chiang, Chi-Lu and Luo, Yung-Hung and Chiu, Chao-Hua and Yen, Sang-Hue and Liu, Chun-Yu and Chiou, Jeng-Fong and Burnouf, Thierry and Chen, Yin-Ju and Wang, Peng-Yuan and Chao, Tsu-Yi and Hsu, Shih-Ming and Lu, Long-Sheng},
title = {Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15039}
}
EUVIMED